Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Melanoma
Interventions
DRUG

Pimonidazole

Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hypoxyprobe

UNKNOWN

lead

Yana Najjar

OTHER